Greece · Delayed Price · Currency is EUR Lavipharm Statistics
Total Valuation
Lavipharm has a market cap or net worth of EUR 264.02 million. The enterprise value is 290.69 million.
| Market Cap | 264.02M |
| Enterprise Value | 290.69M |
Important Dates
The last earnings date was Thursday, May 28, 2026.
| Earnings Date | May 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Lavipharm has 170.78 million shares outstanding.
| Current Share Class | 170.78M |
| Shares Outstanding | 170.78M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 2.18% |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 51.78.
| PE Ratio | 51.78 |
| Forward PE | n/a |
| PS Ratio | 4.09 |
| PB Ratio | 4.68 |
| P/TBV Ratio | 18.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 56.16 |
| EV / Sales | 4.50 |
| EV / EBITDA | 20.62 |
| EV / EBIT | 32.68 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.58 |
| Debt / EBITDA | 2.32 |
| Debt / FCF | n/a |
| Interest Coverage | 4.94 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 7.10% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 9.14% |
| Revenue Per Employee | 226,435 |
| Profits Per Employee | 18,161 |
| Employee Count | 285 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Lavipharm has paid 2.63 million in taxes.
| Income Tax | 2.63M |
| Effective Tax Rate | 33.70% |
Stock Price Statistics
The stock price has increased by +95.70% in the last 52 weeks. The beta is 1.01, so Lavipharm's price volatility has been similar to the market average.
| Beta (5Y) | 1.01 |
| 52-Week Price Change | +95.70% |
| 50-Day Moving Average | 1.49 |
| 200-Day Moving Average | 1.10 |
| Relative Strength Index (RSI) | 45.75 |
| Average Volume (20 Days) | 167,629 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Lavipharm had revenue of EUR 64.53 million and earned 5.18 million in profits. Earnings per share was 0.03.
| Revenue | 64.53M |
| Gross Profit | 30.86M |
| Operating Income | 8.89M |
| Pretax Income | 7.81M |
| Net Income | 5.18M |
| EBITDA | 13.30M |
| EBIT | 8.89M |
| Earnings Per Share (EPS) | 0.03 |
Balance Sheet
The company has 6.11 million in cash and 32.78 million in debt, with a net cash position of -26.67 million or -0.16 per share.
| Cash & Cash Equivalents | 6.11M |
| Total Debt | 32.78M |
| Net Cash | -26.67M |
| Net Cash Per Share | -0.16 |
| Equity (Book Value) | 56.41M |
| Book Value Per Share | 0.33 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 4.41M |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 47.81%, with operating and profit margins of 13.78% and 8.02%.
| Gross Margin | 47.81% |
| Operating Margin | 13.78% |
| Pretax Margin | 12.11% |
| Profit Margin | 8.02% |
| EBITDA Margin | 20.61% |
| EBIT Margin | 13.78% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.02, which amounts to a dividend yield of 1.28%.
| Dividend Per Share | 0.02 |
| Dividend Yield | 1.28% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 1.28% |
| Earnings Yield | 1.96% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 1, 2022. It was a reverse split with a ratio of 0.3333333333.
| Last Split Date | Aug 1, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.3333333333 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |